Manish Patel, MD
Payments from drug & device makers
Across 579 payments — averaging $368.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$150K
- Neotract Inc.$18K
- Teleflex LLC$17K
- Axonics, Inc.$6K
- Intuitive Surgical$3K
- Integra Lifesciences Corporation$3K
- plus $15K from 31 others
Across 1 payment — averaging $2254.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neotract Inc.$2K
What the payments were for
- Royalty or licence$69,40333%
- Consulting fees$30,99115%
- Speaking & faculty fees$14,1007%
- Travel & lodging$19,1099%
- Food & beverage$31,64115%
- Education$47,96322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 234 | $150,426 |
| Neotract Inc. | 37 | $18,099 |
| Teleflex LLC | 48 | $17,439 |
| Axonics, Inc. | 48 | $6,187 |
| Intuitive Surgical | 12 | $3,024 |
| Integra Lifesciences Corporation | 3 | $3,001 |
| Derma Sciences, Inc. | 6 | $2,854 |
| Medtronic(2 entities) | 32 | $1,987 |
| Boston Scientific | 18 | $1,489 |
| AstraZeneca | 3 | $1,432 |
| Histosonics, Inc. | 2 | $1,178 |
| Laborie Medical Technologies Corp. | 13 | $981 |
| Calyxo, Inc. | 8 | $967 |
| Johnson & Johnson | 25 | $727 |
| Astellas Pharma US Inc | 22 | $529 |
| Myriad Genetic Laboratories, Inc. | 8 | $526 |
| Janssen Scientific Affairs, LLC | 3 | $283 |
| Foundation Medicine, Inc. | 2 | $265 |
| Agiliti Surgical, Inc. | 3 | $260 |
| Urogen Pharma, Inc. | 1 | $177 |
| Amgen | 8 | $146 |
| Bayer | 2 | $141 |
| Femselect Inc. | 1 | $131 |
| Dendreon Pharmaceuticals LLC | 4 | $130 |
| Novo Nordisk | 2 | $130 |
| Duchesnay USA Incorporated | 10 | $126 |
| Procept Biorobotics Corporation | 1 | $108 |
| Rigicon,inc. | 1 | $102 |
| Endo Pharmaceuticals Inc. | 4 | $74 |
| Pfizer | 5 | $68 |
| Merck | 3 | $55 |
| Myovant Sciences Inc. | 2 | $46 |
| AbbVie | 2 | $38 |
| Urovant Sciences Inc | 2 | $29 |
| Tolmar Pharmaceuticals, Inc. | 2 | $26 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Agiliti Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTORELLE$75,780
- ALTIS$64,605
- UroLift$26,557
- UroLift System$7,144
- Axonics$4,441
- BILAYER WOUND MATRIX (BWM)$3,000
- FLOWABLE$3,000
- INTEGRA WOUND MATRIX (IWM)$3,000
- IDRT$3,000
- Bulkamid$2,894
- BIOFIX$2,815
- BIODRESTORE$1,500
- TENOGLIDE$1,500
- DAVINCI XI$1,500
- LYNPARZA$1,395
- TITAN$1,366
- Da Vinci Surgical System$1,330
- Coloplast TFL Drive$1,160
- CVAC Aspiration System$952
- Optilume BPH Drug Coated Balloon Catheter$543
How this compares
$213,207 in reported general payments places this provider in the 95th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 27 | $30,487 |
| Methenamine Hippurate | 85 | $10,024 |
| Tamsulosin Hcl | 287 | $3,913 |
| Silodosin | 14 | $1,705 |
| Solifenacin Succinate | 31 | $1,019 |
| Finasteride | 41 | $334 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $178 |
| Oxybutynin Chloride | 12 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $529 | $30,48727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 196 urology providers in South Carolina.
Other urology in Elgin
- Neal ShoreMyrtle Beach$63.3M
- Sandip PrasadCharleston$2.4M
- Stephen SavageCharleston$2.1M
- Justin EllettN Charleston$727K
- Thomas KeaneCharleston$281K
- Kimberly BurgessGreenville$271K
- William LowranceGreenville$201K
- Joseph BusbyGreenville$185K
- Abhishek SrivastavaMyrtle Beach$121K
- Matvey TsivianCharleston$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.